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Abstract
Background: Cost of illness studies show that Parkinson disease (PD) is costly for individuals, the
healthcare system and society. The costs of PD include both direct and indirect costs associated
with falls and related injuries.
Methods: This protocol describes a prospective economic analysis conducted alongside a
randomised controlled trial (RCT). It evaluates whether physical therapy is more cost effective than
usual care from the perspective of the health care system. Cost effectiveness will be evaluated using
a three-way comparison of the cost per fall averted and the cost per quality adjusted life year saved
across two physical therapy interventions and a control group.
Conclusion: This study has the potential to determine whether targetted physical therapy as an
adjunct to standard care can be cost effective in reducing falls in people with PD.
Trial Registration: No: ACTRN12606000344594
Background
Parkinson disease (PD) is a progressive neurodegenerative
disorder that mainly affects older individuals. The preva-
lence rates of Parkinson disease are estimated at 1 per cent
in people aged over 60 years and between 0.15 and 0.3 per
cent in the general population with a mean age of onset in
the mid sixties [1-3]. The burden of disease associated
with PD is substantial, impacting on individuals, the
healthcare system and society [4].
Hypokinesia, rigidity, rest tremor and postural instability
in later stages of the disease are the major motor symp-
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toms of PD [5]. These can progressively restrict mobility
and increase the risk of falls [1,5]. Other than motor
impairments, PD can affect cognitive function [6] and
mood [7]. In some people it can also be associated with
dementia [8], sleep alterations, sensory symptoms and
autonomic dysfunction [1]. Studies indicate that fatigue,
pain and depression are symptoms that have significant
impacts on quality of life of people with PD [1,9]. Thus in
the latter stages of disease progression PD can be associ-
ated with significant disability. Deteriorating functional-
ity and loss of mobility associated with PD typically occur
at a time when people are also susceptible to ageing-
related changes, compounding these "normal ageing"
symptoms [1].
Currently there is no known cure for PD and evidence of
effectiveness of neuro-protective agents that slow the pro-
gression of the disease is inconclusive [1]. Pharmacother-
apy is the most common treatment for motor symptoms
although it is reported that complications such as motor
fluctuations and dyskinesia are associated with long-term
use [1]. A recent systematic review and meta-analysis of
the effectiveness of exercise interventions in people with
PD found empirical evidence that exercise was beneficial
for people with PD with regards to physical functioning,
strength and balance and health-related quality of [10].
Annual falls incidence rates in people with PD have been
reported to range from 50 – 68 per cent [11-13]. Not only
is the risk of falling increased with PD, but the risk of seri-
ous falls and falls resulting in injury, particularly hip frac-
ture also increases [14-17]. One study has estimated that
27% of people with PD will sustain a hip fracture in the
first 10 years following diagnosis of PD [15]. Predictors of
falls include number of falls in the previous year, Hoehn
and Yahr stage and 'fear of falling', however the relation-
ship between falls and PD severity combined with level of
activity has not been established [17].
A number of costs of illness studies conducted to assess
the social and economic burden of PD have shown that
PD is costly for individuals, the health-care system and
society more broadly [4,18-25]. Drug therapy is a major
contributor to direct health care costs [4,21-23], while
individuals and their carers also face home care costs and
may suffer high productivity losses [4]. Although the costs
of falls and fall-related injuries have not been separately
analysed in cost of illness studies associated with PD, falls
are likely to incur both direct and indirect costs. These
include increased costs from health-care service utiliza-
tion, sustained productivity losses, and impacts on carer
quality of life in terms of depression [18], fear for their
spouse, and carer injuries sustained while preventing their
spouse's falls [19].
A recent New Zealand community-based falls prevention
study in an elderly population suggests that falls interven-
tion programs can be cost effective, finding that a home
safety program cost $432 per fall prevented [26]. Any
intervention that is cost-effective at reducing aspects of the
burden of PD, in this case falls, could have important eco-
nomic benefits for patients and families, and for the
health-care system as a whole.
From the perspective of the health system, this prospective
economic analysis addresses whether physical therapy is
more cost effective than standard care in terms of the
number of falls prevented, the number of injurious falls
prevented and improvement in health related quality of
life (HRQoL). The incremental cost per fall prevented,
cost per injurious fall prevented, cost per quality adjusted
life year saved are predicted to be less for the two active
therapy groups (PRT and MST) than for the control group.
No statistically significant difference is predicted between
the PRT and MST intervention groups.
Methods
This study incorporates a prospective economic analysis
alongside a randomized controlled trial (RCT). The eco-
nomic analysis takes the perspective of the health-care sys-
tem and compares two different physiotherapy programs
(movement strategy training (MST) and progressive resist-
ance strength training (PST)) with usual PD care (control
group receiving a PD education program without falls
education). The three interventions are compared to
assess relative cost effectiveness where benefits are meas-
ured in terms of two intermediate clinical outcomes, 'falls
prevented' and 'injurious falls prevented' and an eco-
nomic outcome endpoint HRQoL.
Movement strategy training (MST)
The MST intervention group receives an 8 week outpatient
program consisting of a once-weekly physical therapy ses-
sion (usually provided in groups of 4), which comprises
strategies to prevent falls, enhance balance and improve
mobility as defined by Morris [27]. Education about risk
factors for falls and strategies for reducing falls in the
home is included. Participants also complete a home pro-
gram of exercises once a week. During the 8 weeks each
individual also receives one home visit by an occupa-
tional therapist (OT), physical therapist or nurse where
compliance with the program is monitored.
Progressive resistance strength training (PRT)
The PRT intervention group receive an 8 week outpatient
program consisting of a once weekly 60 minute individu-
alized strengthening program. Resistance is progressively
increased and all exercises are functional in design. Partic-
ipants are also instructed on how to complete the exer-
cises once a week at home. Appropriate equipment
BMC Geriatrics 2008, 8:23 http://www.biomedcentral.com/1471-2318/8/23
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including a weighted vest is provided for this purpose. As
with the MST intervention, people in the PRT intervention
group also receive a home visit.
Control intervention
The control intervention is an 8 week, once weekly, 60
minute outpatient social activity and PD education pro-
gram, with an additional activity performed once a week
at home. During the program, each person also receives a
home visit (as described above).
Co-interventions
The study does not restrict participants from accessing
their usual care or any other activities. It is predicted that
a small number of participants might access other physi-
cal therapy services, or home modification during the
intervention and 12-month follow-up period. The base-
line, 3 month and 12 month follow-up questionnaires
were designed to capture this information.
Study population
Participants are recruited into the RCT from specialist out-
patient movement disorder clinics and private neurolo-
gists and physical therapists in the Melbourne
metropolitan area as well as from advertising in local
newspapers. All participants recruited for the RCT are
included in the cost effectiveness analysis. To be included,
participants are required to have idiopathic PD, be willing
and able to provide informed consent, able to walk and
safely participate in an exercise program and have the abil-
ity to travel to the outpatient clinic for the 8 weeks of ther-
apy and for 4 testing sessions. People are excluded if they
scored less than 24 on the Mental State Examination
(MMSE) [28], if they are Hoehn and Yahr Stage V [29]
(bed or wheelchair-bound), or if they are on major tran-
quilizers.
Sample size
Due to the paucity of trials in people with PD using pro-
spective falls as an outcome measure, the sample size cal-
culation for the study was inherently speculative. Falls
rates were initially determined based on data from a pre-
vious study of people with PD and older people without
PD [30]. The minimum sample size per group required to
obtain a statistically significant difference in falls fre-
quency between the control group (with an estimated
60% falls rate) and the PST or MRT groups (with a 40%
rate) was calculated as 110 participants (D = 0.05, E =
80%, 10% drop-out rate). However, a recent blinded
interim assessment of the falls data indicated a far higher
falls rate than initially expected (over 800 falls reported by
93 participants enrolled). An interim analysis by an exter-
nal data monitoring committee is scheduled in the near
future and will consider intervention efficacy, safety and
sample size.
Blinding
All participants are tested four times by a trained blinded
independent assessor: prior to and at the completion of
each 8 week intervention, and 3 months and 12 months
after completion of the intervention.
Ethics Approval
Ethics approvals were obtained from the Southern Health
Human Research Ethics Committee (HREC Number
060035) and The University of Melbourne Health Sci-
ences Human Ethics Sub-Committee (Number 0828579)
of Australia.
Measures of outcomes
An intervention aimed at improving strength or mobility
and reducing falls in people with PD is likely to have an
immediate effect on both health outcomes and HRQoL.
We have therefore incorporated a range of outcome meas-
ures aimed at detecting these changes in our core set of fall
outcome measures. The primary clinical outcome meas-
ure is falls frequency (number of falls per person). A fall
has been broadly defined as an unexpected event in which
the participant comes to rest on the ground, floor or lower
level [31,32]. This definition is consistent with the litera-
ture on falls prevention. Changes in HRQoL will be meas-
ured using both a PD-specific measure (PDQ-39) [33] and
a generic utility instrument (Euroqol-5D) [34] adminis-
tered at baseline, immediately post-intervention, 3
months, and 12 months.
Measures of cost
From the health care-system perspective costs incorporate
the direct costs of each intervention, including the costs of
running the interventions themselves, the costs to the par-
ticipants of accessing the intervention and any relevant
downstream health costs or savings. These costs (and sav-
ings) will be quantified, valued, and aggregated to deter-
mine total and marginal cost estimates per unit of
outcome.
Direct costs
Direct costs of delivering the interventions will include
the resource costs of running the physiotherapy training,
the Falls Prevention Education Program, and conducting
the home visit. Cost categories will include staff costs
(therapists and allied health assistants), equipment (such
as weight training equipment used in the PRT interven-
tion), space, capital, overheads, and consumables (educa-
tion materials). Program development costs will be
attributed to each intervention, capturing the costs of
training staff to deliver the interventions and developing
the intervention protocols.
The costs/savings of health services utilization resulting
from events relating to falls and related injuries will be
BMC Geriatrics 2008, 8:23 http://www.biomedcentral.com/1471-2318/8/23
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valued to capture the changes in service use associated
with reduced falls that result from the interventions. This
requires identifying:
• healthcare costs resulting from events relating to falls
and related injuries;
• the number and severity of injuries resulting from falls
(by injury type);
• the number of hospitalizations and length of stay attrib-
utable to falls related injuries; and
• the number of people requiring institutional care fol-
lowing falls injuries.
The direct costs or out-of-pocket payments associated
with the interventions that are borne by patients and/or
their families will be included. From the health care sys-
tem perspective the costs of access (transportation) to and
from the intervention is likely to be the primary direct per-
sonal cost associated with the intervention.
Indirect costs
Indirect costs associated with the interventions will be
included in the analysis. These are the opportunity cost for
participants and their carers of the intervention (patient
time), and productivity gains/losses in work and leisure
that result from the intervention.
Exclusion of trial costs
All setup costs and other costs related to the clinical trial
will be excluded. These include costs associated with trial
administration, data collection, and actual measurement
of clinical outcomes as per the trial protocol.
Results
Outcome data
A falls incidence reporting system has been designed to
collect comprehensive falls data, comprising a falls calen-
dar, a falls telephone hotline, and regular 'falls-specific'
calls to frequent 'fallers' for clarity and completeness [32].
The questions relating to economic data associated with
each fall are shown in Figure 1. Following a fall, partici-
pants record the event on an especially designed calendar
and telephone the 'Falls Hotline'. A standardized ques-
tionnaire is administered by a trained assistant when a
participant reports a fall through the hotline or in a fol-
low-up phone call for falls reported through the falls cal-
endar. This questionnaire collects important sub-
classification data on the type and cause of the fall and
includes a comprehensive set of questions on any health
service use arising as a result of the fall.
Falls are classified as injurious and non-injurious falls.
Detailed falls classification data are also collected through
the falls follow-up standardized questionnaire on injuries
sustained. Hospitalization information including length
of stay, transport mode to hospital, and details of the hos-
pital, together with other out-patient health care service
utilization (general practitioner, Parkinson's specialist,
physiotherapist, other allied health professional, radiol-
ogy clinic and pathology clinic) are collected. This latter
information will also be used to determine the extent of
injury associated with falls, to define falls as 'injurious' or
'non-injurious' and the associated costs of falls.
Making this distinction between injurious and non-injuri-
ous falls and the data collection strategy developed will
reduce misclassification and reporting errors [31]. Fur-
ther, from a health-care system perspective this distinction
is beneficial in providing more specific and deeper analy-
sis of both the effectiveness and health-care costs/savings
associated with the interventions.
Quality of life data is obtained from the two Quality of
Life surveys (the PDQ-39 questionnaire that collects dis-
ease-specific quality of life data and the Euro-QOL which
generates a generic health quality of life utility measure),
administered to each participant at the baseline, post-
intervention, 3 months, and 12 month interview.
Changes in disability attributable to the intervention are
measured using the Unified Parkinson's Disease Rating
Scale (UPDRS) [35]. This will enable us to stratify falls by
the level of disability.
Cost data
A questionnaire administered to facility managers will
quantify the resource requirements, including staff costs,
rent for space and large capital items, overheads and con-
sumables. Market prices and relevant depreciation rates
will be used to determine other capital and equipment
costs. Sensitivity analysis will be used to vary labour costs
using the award wage rate plus on-costs for superannua-
tion and leave loading, and market fee-for-service charges
for the relevant health professional category.
A questionnaire, to be administered at each therapy ses-
sion, has been designed to capture information on any
injuries or health issues and associated healthcare utilisa-
tion arising as a direct result of the therapy sessions. Per-
sonal costs borne by the individual in accessing the
intervention including time, distance and mode of trans-
port are also included. Costs of each mode of transport
will be estimated using standard taxi charges, the price of
public transport, and a cost per kilometre for a private car.
BMC Geriatrics 2008, 8:23 http://www.biomedcentral.com/1471-2318/8/23
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Data collected through the falls calendar and falls hotline
will be used to quantify fall-related health care service uti-
lization. Valuing or costing health service utilization will
be done using a number of methods. Where patients
attend a hospital in our Southern Health region (which
includes hospital facilities participating in the study), we
will collect patient-level costing and utilization data for
inpatient services from the hospital's computerized cost-
ing and admission discharge systems. This data can then
be used to model costs for patients where patient-level
data is not available, such as if they attend a hospital out-
side the Southern Health region. In this case length of stay
will be used as the main parameter. Costs will be attrib-
uted to these services based on published costing data
from the National Hospital Cost Data Collection, Com-
monwealth Medical Benefits Schedule (CMBS), and the
Pharmaceutical Benefits Scheme (PBS). This approach can
be reconciled with a Diagnosis Related Group (DRG) cost-
ing approach. CMBS rates will be used to cost medical and
diagnostic imaging services, PBS for pharmaceuticals and
award wages for other health professionals.
Cost effectiveness analysis
The benefit of economic evaluation is that it captures both
benefits and costs of an intervention in one comparable
unit – a cost-effectiveness ratio. In this evaluation eco-
nomic analysis will be three-way, first comparing each
intervention with the control group, and then comparing
the interventions with each other. The three-way analysis
of the cost effectiveness ratios is shown in Table 1.
Cost per fall averted
Increased risk of falling is a significant adverse conse-
quence of PD. As such, reduced falls is the primary clinical
outcome of the RCT. The first step of the economic evalu-
ation will be to analyse this intermediate outcome, and do
a three way comparison of the cost per fall averted ratios
of the interventions and the control. This ratio provides a
Economic data/questions included on the Falls QuestionnaireFigure 1
Economic data/questions included on the Falls Questionnaire.
Did you need to go to hospital after  your  fall? 
            YES                  NO 
a) If yes, how did you get to hospital? 
b) If you did go to hospital following the fall, were you admitted overnight? 
c) If yes, how many nights did you stay in hospital? 
Please indicate if you needed to use any of the following out-of-hospital health services 
following your  fall: 
 
i) General Practitioner 
ii) Parkinson disease Specialist 
iii) Physiotherapist 
iv) Other allied Health Professional 
v) Radiology (XRay Clinic) 
vi) Pathology Clinic 
BMC Geriatrics 2008, 8:23 http://www.biomedcentral.com/1471-2318/8/23
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crude measure of cost effectiveness in that the outcome
measure (fall averted) does not distinguish between dif-
ferent levels of severity of falls. However as a standardised
definition it enables greater synthesis with the body of
research in the field and allows comparison with other
falls prevention studies [31].
Cost per injurious fall averted
Falls are broadly defined in this trial, consistent with best
practice in the field [31,32]. However there is significant
variation in the severity of falls and the associated direct
and indirect costs of falls (injury, quality of life conse-
quences, hospital and other medical costs of treatment,
and productivity losses). One intervention may be more
effective at reducing serious falls (resulting in injury)
while another may be more effective at reducing minor
falls. An intervention may also improve the ability of a
person with Parkinson's disease to react, hence minimis-
ing the severity of a fall and changing the type of fall
endured. While cost of hospital use associated with falls is
captured in the first ratio (primary outcome measure),
from a health services perspective it is also meaningful to
differentiate between falls and analyse more specifically
falls associated with injury and subsequent health care
use. We will therefore define an 'injurious fall' as a fall
resulting in an injury requiring a health service contact.
Cost per quality adjusted life year saved
Falling and fear of falling can reduce the quality of life of
individuals with PD in a number of ways. Further it is
expected that physiotherapy treatments may have other
positive impacts on individuals with PD. Comparing
interventions based only on their ability to prevent falls
will not capture the broader impacts and quality of life
changes that may be attributable to the interventions.
There is also limited external comparability of the cost
effectiveness of these interventions with other interven-
tions for people with PD, let alone other diseases. Thus
cost utility analysis will be undertaken comparing the cost
per QALY gained across the two interventions and the
control group.
Discounting and sensitivity analysis
We will define our base year as 2008 so costs in earlier
years will be inflated using the published Australian con-
sumer price index (CPI). One way sensitivity analysis will
be undertaken to investigate the robustness of the CE
ratios to a range of cost and effect estimates, including
staff and program costs and discount rate on the cost side,
and number of falls, number of injurious falls, HRQoL
and PDQ-39 on the effect side.
Discussion
There are a number of important advantages of conduct-
ing an economic evaluation alongside an RCT, especially
where the trial compares complex interventions for a dis-
ease such as PD. Economic input throughout the plan-
ning, design, data collection, implementation and
evaluation and analysis phase of the RCT means that data
can be collected alongside the clinical data in a way that
meets the specific needs of the economic analysis. A cen-
tral database system can be used to store both clinical and
economic data concurrently. Timely data collection
means that recall bias is reduced.
Inclusion of an economist in the design and running of
the RCT results in expert advice regarding the selection of
appropriate outcome measures. In this evaluation, there is
opportunity to access good quality effectiveness data
through careful monitoring of falls outcomes and timely
reporting on quality of life indicators in the same sample
population. Consistency in applying the outcome meas-
urement instruments to the same sample population may
not be available in evaluations using modelling and pub-
lished findings.
The clinical trial setting provides more specific, and some-
times patient-level, resource use and costing data involved
Table 1: Three-way analysis of cost-effectiveness ratios
MST vs Control
Cost per fall averted Cost per injurious fall averted Cost per QALY saved
PRT vs Control
Cost per fall averted Cost per injurious fall averted Cost per QALY saved
MST vs PRT
Cost per fall averted Cost per injurious fall averted Cost per QALY saved
BMC Geriatrics 2008, 8:23 http://www.biomedcentral.com/1471-2318/8/23
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in running the interventions, where estimates can be
modelled from the costs incurred during the trial itself.
Further, more systematic and timely consideration of
costs can take place in this planned environment.
There are potentially some limitations to this methodol-
ogy. Clinical trials are conducted in natural settings, so
treatment compliance, resource utilization and other out-
comes observed in a trial may not reflect what actually
occurs in the real world. Using more real-life setting obser-
vational data or more pragmatic clinical trials could
improve the external validity of an economic evaluation
attached to a clinical trial. In this trial, the intervention
protocols were designed to proximate real-life environ-
ments by running the interventions through out-patient
facilities.
The reporting system for falls established for this RCT and
evaluation is made up of two data capture mechanisms,
the calendar and the falls hotline, which allows for cross-
checking of falls reports. This appears to improve report-
ing rates of fall events and track compliance of the report-
ing mechanism. The standardized questionnaire,
administered when contact is made through the falls hot-
line and/or during a follow-up phone call for calendar
reported falls, is designed to reduce recall bias by reducing
the recall period (maximum of 1 month for falls reported
on the calendar that were not reported through the falls
hotline) and by systematically documenting fall events
and their implications, particularly with respect to health
service use.
Two measures of quality of life have been chosen for this
study, the EuroQoL EQ-5D and the PD-specific PDQ-39.
These tools were chosen due to their simplicity for
respondents, and the documented validity, reliability and
sensitivity to change in the quality of life literature
[32,34,36]. The PDQ-39 captures the specific impacts on
quality of life that relate specifically to people with PD.
The single unitary health utility index derived from the
EQ-5D will enable comparison across a range of interven-
tions, a broad scope of health issues and diseases, and
may also capture "unanticipated effects" not built into the
PDQ-39 [36,37].
Conclusion
This project has the potential to determine whether phys-
ical therapy as an adjunct to the routine medical manage-
ment of PD can be cost effective in reducing falls and
improving quality of life. Evidence of cost effectiveness
can be used to support a case to healthcare funders,
including private insurers for the funding of a complex
physical therapy intervention for people with this disa-
bling neurological condition.
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